Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies

Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies

Abstract Objectives Due to the heterogeneity of PCa, the clinical indicators used for PCa can't satisfy risk prognostication and personalized treatment. It is imperative to develop novel biomarkers for prognosis prediction and therapy response in PCa. Accumulating evidence shows that non-mutati...

Full description

Bibliographic Details
Main Authors: Xiao Tan, Zhouda Cai, Guo Chen, Chao Cai, Jiahong Chen, Yingke Liang, Yangjia Zhuo, Jianming Liu, Liangliang Huang, Bin Ouyang, Yanni Wei, Zhenyu Jia, Junhong Deng, Weide Zhong, Jianming Lu
Format: Article
Language:English
Published: Springer 2023-05-01
Series:Discover Oncology
Subjects:
Prostate cancer
Epigenetics
RNA 5-methylcytosine
Biochemical recurrence
Androgen receptor signaling inhibitor
Immunotherapy
Online Access:https://doi.org/10.1007/s12672-023-00671-w

Internet

https://doi.org/10.1007/s12672-023-00671-w

Similar Items